Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903095 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of TD-1439 in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02903095 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 66 participants.
The verdict
NCT02903095, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects
Interventions
- DRUG Placebo
- DRUG TD-1439
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903095
The ClinicalTrials.gov registry entry for NCT02903095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02903095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903095 about?
NCT02903095 is a clinical study titled "Single Ascending Dose Study of TD-1439 in Healthy Subjects". Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects
What is the current status of trial NCT02903095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2016-09. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02903095?
The interventions under investigation include: Placebo (DRUG), TD-1439 (DRUG).
Who is sponsoring clinical trial NCT02903095?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.